Nūhou

NEW YORK, Iune 23, 2022 (GLOBE NEWSWIRE) - Hoʻolaha ʻo Reportlinker.com i ka hoʻokuʻu ʻana o ka hōʻike "Global Intravenous Therapy and Intravenous Access Market Size, Share and Industry Trends Analysis Report, Outlook and Forecast by End User, Application, Type, Region. , 2022-2028″ - https://www.reportlinker.com/p06283441/?utm_source=GNW ʻO ke ala wikiwiki loa e hoʻokomo i nā wai i nā ʻāpana like ʻole o ke kino ma o ka IV therapy. ʻO ka hoʻouka ʻana o ka naʻau, ka hahau ʻana, a me ka lāʻau make. ʻO kēia lāʻau lapaʻau. Ma kēia hihia, pono e mālama ʻia ka mea maʻi me ka lāʻau lapaʻau i ka wā hiki loa, no laila hāʻawi ʻia ka lāʻau lapaʻau i loko o ke koko. (IV) ʻo ia ke ʻano o ka hāʻawi ʻana i nā lāʻau lapaʻau a me nā wai i loko o ke kino ma o ke aʻa. Hoʻohana ka mea maʻi i kahi paipu i kapa ʻia he cannula e hoʻokomo pololei i nā mea i loko o kahi vein. He hopena ʻaoʻao paha kēia o ka lāʻau a i ʻole ka hemahema o ka meaʻai. I ka wā o ka lawelawe ʻana IV, hoʻohana ʻia nā mea hana IV like ʻole e like me nā catheters IV, nā paila infusion, nā mea immobilization, a me nā pahu hoʻokele. hoʻokuʻu i nā maʻi maʻi maʻi ma mua o ka lāʻau lapaʻau waha. Loaʻa iā ia ka infusion pump e hoʻomalu i ka nui o nā kemika e hoʻolako ʻia i ke kino a hiki ke nānā maʻalahi ʻia. ʻO ka maʻi diabetes, ka piʻi ʻana o nā ulia pōpilikia, a me ka piʻi ʻana o nā kaʻina hana ʻokiʻoki e manaʻo ʻia e hoʻolalelale i ka ʻoihana i mua. He hopena maikaʻi loa ma ka mākeke IV therapy. I nā poʻe maʻi me ka maʻi koʻikoʻi pili i ka COVID-19-related acute respiratory distress syndrome, lawelawe ʻia ka IV therapy (ARDS). ua paʻi ʻia kahi adjuvant maikaʻi no ka mālama ʻana i ka ARDS pili i ka COVID-19 i ka The Lancet Respiratory Medicine ma Nowemapa 11, 2021 no ka mea hiki iā ia ke hoʻololi i nā keʻena immune he nui i ka manawa like. ʻO ARDS e pili ana, ke piʻi nei ka noi no ka IV therapy a me nā huahana intravenous access. ʻO ka maʻi puʻuwai, a me nā ʻano nohona like ʻole e like me ke koko kiʻekiʻe, ka maʻi diabetes, ka momona a me ke kaumaha, pono e mālama koʻikoʻi i ka wā e noho ai i ka haukapila. , hui pū ʻia me ka poʻe ʻelemakule, e hoʻonui i ka pono no ka lāʻau lapaʻau. IVT) hoʻomaʻamaʻa. ʻOiai ʻo ka ʻenehana olakino he aʻo paʻakikī, me ka noʻonoʻo ʻana a me ke kūkākūkā ʻana i kēlā me kēia lā e nā ʻoihana olakino e pili ana i ka mālama maʻi i loko o ka hale mālama koʻikoʻi, ua hoʻololi nui ke kahua mālama ma muli o ka hoʻohui ʻana o nā ʻenehana hou, a ʻO nā pamu infusion ʻokiʻoki ʻO kekahi o nā kumuwaiwai ʻenehana e kōkua i ka hoʻokō ʻana i ka hana intravenous therapy (IVT) palekana a ʻoi aku ka maikaʻi. Nā Mākeke Kūʻai ʻO ka hana ʻana i ka Pump pono nā lula a me nā hopohopo e pili ana i nā pilikia.ʻO ke kaʻina hana laikini no nā papahana hou e alakaʻi ʻia a puni ka hana ʻana a me ka hoʻohui ʻana. Eia kekahi, ʻo ka piʻi ʻana o ka hoʻomanaʻo ʻana o nā huahana ma muli o nā hemahema o ka hana ʻana e hoʻolōʻihi i ka lawe ʻana i kēia mau lāʻau lapaʻau. ʻAukake 2019 ma muli o nā pilikia makaʻala infusion, mālama haʻahaʻa haʻahaʻa e mālama i ka Vein Open (KVO) a me nā polokalamu polokalamu ʻē aʻe. ma ka mea hoʻohana hope, ua hoʻokaʻawale ʻia ka mākeke i loko o nā haukapila, nā keʻena ʻoihana ambulatory, a me nā keʻena. o nā ʻokiʻoki i hana ʻia i ka hoʻohālikelike ʻia me nā kikowaena o ke kaʻina hana ambulatory a me nā keʻena. radiology, anticancer drugs, hemodialysis, repeat blood sample mapping, and blood transfusions .Ke ulu nei ka mākeke no ka IV therapy a me nā mea komo venous ma muli o ka holomua ʻenehana a me nā hoʻopukapuka halemai. , nā huahana pili koko, nā meaʻai a me nā hoʻonā pale, a me nā moku hoʻonui. I ka makahiki 2021, e loaʻa i ka ʻāpana Volume Expander ka loaʻa kālā nui ma ka intravenous (IV) therapy and venous access market. - nā mea pāʻani koʻikoʻi;akā naʻe, pono e mālamaʻia kēia no nā poʻe haʻuki kiʻekiʻe me ka moʻolelo o nā hōʻailona ikaika ma lalo o ka nānā maikaʻi. ʻO ka maʻamau IV therapy ʻaʻole ke koho maikaʻi loa. Type Outlook Ma muli o ke ʻano, ua māhele ʻia ka mākeke i loko o nā catheters intravenous, infusion pumps, hypodermic needles, implantable ports, a me nā mea ʻē aʻe. intravenous (IV) therapy and venous access market. ʻO kēia ma muli o ka hoʻonui ʻia o ka hoʻohana ʻana i nā catheters IV i ka wā o ke kaʻina hana no ka IV therapy a i ka wā o ka hoʻoili ʻana o ke koko, nā lāʻau lapaʻau, a me nā meaʻai ʻē aʻe i nā wahi like ʻole o ke kino. Hoʻokomo ʻia i loko o ka lua o ke kino a i ʻole lumen. ʻO ka catheter intravenous he mea hoʻoheheʻe intravenous i hoʻohana ʻia no ka lawe ʻana i nā lāʻau lapaʻau, wai, a i ʻole nā ​​​​mea lapaʻau ʻē aʻe i loko o ke kahe koko. ʻāʻī, ka umauma, a i ʻole ka ʻāʻī. Hele mai nā catheters intravenous i nā ʻano nui a me nā ʻano, e pili ana i ko lākou manaʻo e hoʻohana. .I ka makahiki 2021, ʻo ʻAmelika ʻĀkau ka ʻāina alakaʻi i ka intravenous (IV) therapy a me ka mākeke komo venous ma o ka hopu ʻana i ka mahele o ka mākeke kiʻekiʻe loa. nā ulia pōpilikia, ulu kiʻekiʻe i nā hihia trauma, a me ka hoʻonui ʻana i nā hoʻopukapuka federal i ka hoʻomohala ʻana i nā keʻena olakino maikaʻi a me nā hana R&D. ʻO ka hōʻike noiʻi mākeke e uhi i ka loiloi o nā mea kuleana nui o ka mākeke. Medtronic PLC, Terumo Corporation, Fresenius SE & Co. KGaA, Cardinal Health, Inc., Pfizer, Inc., Teleflex, Inc., Baxter International, Inc., Smiths Group PLC a me AngioDynamics, Inc. ) Therapy and Intravenous Access Market Malaki 2022: Ua kau inoa ʻo Fresenius Kabi i kahi ʻaelike e loaʻa iā Fresenius Kabi, kahi hui mālama ola honua. hui ākea o nā huahana i nā halemai US. Kekemapa 2021: Hoʻokumu ʻo Baxter i ka hui pū ʻana me ka mea lawelawe ʻenehana lapaʻau US Hillrom. .Mei 2021: Hoʻokumu ʻo Smiths Medical i ka hui pū ʻana me ka hui ʻenehana lapaʻau ʻo Ivenix. Ma o kēia hui ʻana, manaʻo nā hui ʻelua e hāʻawi i kahi ākea ākea o ka hoʻokele infusion. a hoʻonui i ke olakino maʻi, ʻoiai e hālāwai ana i nā pono o nā mea mālama ola. ʻApelila 2021: Ua hoʻokumu ʻo B. Braun Medical i kahi papahana hou, Peripheral Advantage, e hoʻomaikaʻi i ka ʻike o nā maʻi me ka peripheral intravenous therapy. The program integrates clinical guidance, data-driven intuition, and nā mea hana i hoʻomaikaʻi ʻia e hoʻoikaika i nā kahu hānai e hoʻokō i ka kūleʻa mua a kōkua i ka pale ʻana i nā pilikia e pili ana i ka peripheral IV therapy.Iulai 2019: Loaʻa iā Baxter ka ʻae ʻana o ka US Food and Drug Administration (FDA) no Myxredlin. a me nā hoʻonohonoho mālama koʻikoʻi ʻē aʻe a he 30 mau lā a i ʻole 24 mau mahina ma ka lumi wela inā hoʻokomo ʻia i loko o ka pahu hau i loko o ka pahu hau e hōʻoia i ka pale ʻana mai ka mālamalama. Nā hōʻike: Na ka mea hoʻohana hope. • Nā Huahana Koko • Nā meaʻai a me nā mea hoʻoponopono hoʻopaʻa • Nā Waʻa Diffusion ma ke ʻano • Intravenous Catheters • Infusion Pumps • Hypodermic Needles • Implantable Ports • Other by Geography • North America o USo Canadao Mekiko Ke koena o ʻAmelika ʻĀkau • ʻEulopa Kelemānia o UKo Farani Rusia Sepania Italia o ʻO ke koena o ʻEulopa • Asia Pacific Kina o Iapana India Korea Singapore Malaysia o ke koena o Asia Pacific • LAMEAo Brazil Argentina UAE Saudi Arabia South Africa Nigeria LAMEA Rest Company Profile• B. Braun Melsungen AG • Medtronic PLC• Terumo Corporation• Fresenius SE & Co. KGaA• Cardinal Health, Inc.• Pfizer, Inc.• Teleflex, Inc.• Baxter International, Inc.• Smiths Group PLC• AngioDynamics, Inc. Nā Hāʻawi Kūʻokoʻa • Hoʻopiʻi Loaʻa • Nā Papa Kūʻai Kūʻai Nui loa a me nāʻikepili • Loaʻa i nā kumu hoʻohālike e pili ana i ke kau inoa. • Hoʻopaʻa ʻia ke kumu kūʻai maikaʻi loa • No ka noiʻi ʻana ma hope o ke kūʻai ʻana i kākoʻo ʻia e 10% Customization E heluhelu i ka hōʻike piha no ka manuahi: https://www .reportlinker.com/p06283441/?utm_source=GNWAbout ReportlinkerReportLinker he hopena noiʻi mākeke lanakila. a hoʻonohonoho i nā ʻikepili ʻoihana hou loa i hiki iā ʻoe ke loaʻa nā noiʻi mākeke āpau āu e pono ai ma kahi hoʻokahi.______________________________